VOR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
58.4M
+22.1%
47.9M
+36.1%
35.2M
-2.2%
36.0M
+27.9%
28.1M
R&D
34.5M
+33.2%
25.9M
+47.3%
17.6M
-8.3%
19.2M
+35.7%
14.1M
SG&A
23.9M
+9.0%
21.9M
+24.9%
17.6M
+4.7%
16.8M
+20.1%
14.0M
Operating Income
-58444000
-22.1%
-47853000
-36.1%
-35160000
+2.2%
-35960000
-27.9%
-28107000
EBITDA
-58405000
-22.1%
-47817000
-36.1%
-35132000
+2.2%
-35937000
-27.9%
-28105000
Net Income
-86727000
-38.1%
-62810000
+71.4%
-219585000
-112.7%
1.7B
+312.0%
-812684000
EPS (Basic)
$-1.45
-25.0%
$-1.16
+77.3%
$-5.11
-106.0%
$84.87
+169.8%
$-121.63
EPS (Diluted)
$-1.45
-25.0%
$-1.16
+77.3%
$-5.11
-106.0%
$84.87
+169.8%
$-121.63
Shares (Diluted)
59.7M
+9.9%
54.3M
+26.3%
43.0M
+111.9%
20.3M
+203.8%
6.7M
Vor Biopharma (VOR) — Financials